{"DataElement":{"publicId":"12430795","version":"1","preferredName":"Clinical Trial Protocol Planned Chemotherapy Regimen or Agent Combination Type","preferredDefinition":"A response used to indicate the planned chemotherapy treatment regimen for the participant.","longName":"7639463v1.00:12430772v1.00","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"7639463","version":"1","preferredName":"Clinical Trial Protocol Planned Chemotherapy","preferredDefinition":"A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the ICH GCP Guideline the term protocol refers to protocol and protocol amendments. NOTE: Present usage can refer to any of three distinct entities: 1) the plan (i.e., content) of a protocol, 2) the protocol document, and 3) a series of tests or treatments (as in oncology). [ICH E6 Glossary]_To devise, contrive, or form in design._The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","longName":"6378855v1.0:7639461v1.0","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"6378855","version":"1","preferredName":"Clinical Trial Protocol","preferredDefinition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents. (ICH)","longName":"C142451","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Trial Protocol","conceptCode":"C142451","definition":"A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the ICH GCP Guideline the term protocol refers to protocol and protocol amendments. NOTE: Present usage can refer to any of three distinct entities: 1) the plan (i.e., content) of a protocol, 2) the protocol document, and 3) a series of tests or treatments (as in oncology). [ICH E6 Glossary]","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"71FC5069-00EC-69F1-E053-F662850A3154","latestVersionIndicator":"Yes","beginDate":"2018-07-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-27","modifiedBy":"ONEDATA","dateModified":"2018-07-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7639461","version":"1","preferredName":"Plan Chemotherapy","preferredDefinition":"To devise, contrive, or form in design.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","longName":"C25619:C15632","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plan","conceptCode":"C25619","definition":"To devise, contrive, or form in design.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C07D01DE-0576-503B-E053-4EBD850A5B8A","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008528","version":"1","preferredName":"Protocol Administration","preferredDefinition":"the management of a research protocol and its case report forms.","longName":"PROT_ADM","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECAD41-A932-34B1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C07D01DE-0587-503B-E053-4EBD850A5B8A","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-04-21","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeDescription":"12/9/21 TL released AI. S1934; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"12430772","version":"1","preferredName":"Chemotherapy Regimen or Agent Combination Type","preferredDefinition":"A combination of multiple drugs used in standard or clinical trial treatments. The order, dosage or dosing interval of the individual ingredients may not be specified._Something distinguishable as an identifiable class based on common qualities.","longName":"12430772v1.00","context":"SWOG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"1","valueDescription":null,"ValueMeaning":{"publicId":"12430773","version":"1","preferredName":"Weekly Paclitaxel x 12","longName":"12430773v1.00","preferredDefinition":"Every week._The reason of something._A natural number greater than 11 and less than 13 and the quantity that it denotes._Any period of seven consecutive days._A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Weekly","conceptCode":"C67069","definition":"Every week.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"For","conceptCode":"C64956","definition":"The reason of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Twelve","conceptCode":"C113426","definition":"A natural number greater than 11 and less than 13 and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Week","conceptCode":"C29844","definition":"Any period of seven consecutive days.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2F19544-065F-299C-E053-731AD00AC045","latestVersionIndicator":"Yes","beginDate":"2023-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-01-23","modifiedBy":"FINCHAMB","dateModified":"2023-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2F19544-0660-299C-E053-731AD00AC045","beginDate":"2023-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-01-23","modifiedBy":"FINCHAMB","dateModified":"2023-01-23","deletedIndicator":"No"},{"value":"2","valueDescription":null,"ValueMeaning":{"publicId":"12430791","version":"1","preferredName":"Weekly Paclitaxel x 12 with Carboplatin","longName":"12430791v1.00","preferredDefinition":"Every week._The reason of something._A natural number greater than 11 and less than 13 and the quantity that it denotes._Any period of seven consecutive days._A regimen consisting of carboplatin and paclitaxel that may be used for the treatment of endometrial, ovarian, head and neck, and advanced-stage non-small cell lung cancer (NSCLC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Weekly","conceptCode":"C67069","definition":"Every week.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"For","conceptCode":"C64956","definition":"The reason of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Twelve","conceptCode":"C113426","definition":"A natural number greater than 11 and less than 13 and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Week","conceptCode":"C29844","definition":"Any period of seven consecutive days.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carboplatin/Paclitaxel Regimen","conceptCode":"C63402","definition":"A regimen consisting of carboplatin and paclitaxel that may be used for the treatment of breast, kidney, cervical, vulvar, endometrial, ovarian, fallopian tube, primary peritoneal, head and neck, and advanced-stage non-small cell lung cancer (NSCLC); anal, small bowel, anaplastic and certain bladder adenocarcinomas; salivary gland, malignant germ cell and malignant sex cord-stromal tumors;  cutaneous and uveal melanoma; thymomas and thymic carcinoma; occult primary adenocarcinoma or squamous cell carcinoma. Paclitaxel/carboplatin every 21 days regimen may be used for the treatment of esophageal and esophagogastric junction, and gastric cancers. Paclitaxel plus intraperitoneal (IP) carboplatin plus IP paclitaxel regimen can be used in the treatment of ovarian, fallopian tube, and primary peritoneal cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2F22CD9-2755-477D-E053-731AD00A6692","latestVersionIndicator":"Yes","beginDate":"2023-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-01-23","modifiedBy":"FINCHAMB","dateModified":"2023-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2F22CD9-2756-477D-E053-731AD00A6692","beginDate":"2023-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-01-23","modifiedBy":"FINCHAMB","dateModified":"2023-01-23","deletedIndicator":"No"},{"value":"3","valueDescription":null,"ValueMeaning":{"publicId":"12430793","version":"1","preferredName":"q3 Weeks Paclitaxel/Carboplatin","longName":"12430793v1.00","preferredDefinition":"Every three weeks._A regimen consisting of carboplatin and paclitaxel that may be used for the treatment of endometrial, ovarian, head and neck, and advanced-stage non-small cell lung cancer (NSCLC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Every Three Weeks","conceptCode":"C64535","definition":"Every three weeks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carboplatin/Paclitaxel Regimen","conceptCode":"C63402","definition":"A regimen consisting of carboplatin and paclitaxel that may be used for the treatment of breast, kidney, cervical, vulvar, endometrial, ovarian, fallopian tube, primary peritoneal, head and neck, and advanced-stage non-small cell lung cancer (NSCLC); anal, small bowel, anaplastic and certain bladder adenocarcinomas; salivary gland, malignant germ cell and malignant sex cord-stromal tumors;  cutaneous and uveal melanoma; thymomas and thymic carcinoma; occult primary adenocarcinoma or squamous cell carcinoma. Paclitaxel/carboplatin every 21 days regimen may be used for the treatment of esophageal and esophagogastric junction, and gastric cancers. Paclitaxel plus intraperitoneal (IP) carboplatin plus IP paclitaxel regimen can be used in the treatment of ovarian, fallopian tube, and primary peritoneal cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2F240A3-1084-4A75-E053-731AD00A684D","latestVersionIndicator":"Yes","beginDate":"2023-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-01-23","modifiedBy":"FINCHAMB","dateModified":"2023-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2F240A3-1085-4A75-E053-731AD00A684D","beginDate":"2023-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-01-23","modifiedBy":"FINCHAMB","dateModified":"2023-01-23","deletedIndicator":"No"},{"value":"4","valueDescription":null,"ValueMeaning":{"publicId":"12430794","version":"1","preferredName":"q3 Weeks Docetaxel/Carboplatin","longName":"12430794v1.00","preferredDefinition":"Every three weeks._A regimen consisting of carboplatin and docetaxel that can be used in the treatment of non-small cell lung cancer (NSCLC) and ovarian cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Every Three Weeks","conceptCode":"C64535","definition":"Every three weeks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carboplatin/Docetaxel Regimen","conceptCode":"C63631","definition":"A regimen consisting of carboplatin and docetaxel that can be used in the treatment of non-small cell lung cancer (NSCLC), breast, head and neck, ovarian, fallopian tube, primary peritoneal, prosate and endometrial cancers, malignant germ cell tumors, and occult primary adenocarcinomas and squamous cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2F24BF3-F5CB-4BDC-E053-731AD00A6EDA","latestVersionIndicator":"Yes","beginDate":"2023-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-01-23","modifiedBy":"FINCHAMB","dateModified":"2023-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2F24BF3-F5CC-4BDC-E053-731AD00A6EDA","beginDate":"2023-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-01-23","modifiedBy":"FINCHAMB","dateModified":"2023-01-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"12430771","version":"1","preferredName":"Chemotherapy Regimen or Agent Combination Type","preferredDefinition":"A combination of multiple drugs used in standard or clinical trial treatments. The order, dosage or dosing interval of the individual ingredients may not be specified._Something distinguishable as an identifiable class based on common qualities.","longName":"12430771v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy Regimen or Agent Combination","conceptCode":"C12218","definition":"A combination of multiple drugs used in standard or clinical trial treatments. The order, dosage or dosing interval of the individual ingredients may not be specified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2F1723F-2708-2212-E053-731AD00AEAE5","latestVersionIndicator":"Yes","beginDate":"2023-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-01-23","modifiedBy":"FINCHAMB","dateModified":"2023-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2F1723F-2709-2212-E053-731AD00AEAE5","latestVersionIndicator":"Yes","beginDate":"2023-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-01-23","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What is the participant's planned chemotherapy regimen?","url":null,"context":"SWOG"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2F27178-AC4C-54A3-E053-731AD00A2B3F","latestVersionIndicator":"Yes","beginDate":"2023-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-01-23","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeDescription":null,"administrativeNotes":"1/23/23 Created for SWOG. BF;","unresolvedIssues":null,"deletedIndicator":"No"}}